What we do Acutaas Chemicals Limited manufactures advanced pharmaceutical intermediates and specialty chemicals, serving pharma, semiconductor, battery, cosmetic, agrochemical sectors with cutting-edge R&D and sustainable processes. |
Founded in 2,004 |
Market share Leading Indian manufacturer of pharmaceutical intermediates with growing presence in specialty chemicals and expanding international footprint, commanding significant market share in its niche segments. |
Problem solved Provides cost-effective, high-quality intermediates and specialty chemicals enabling generic drug production, clean energy solutions, and semiconductor materials, aiding global pharma and technology industries. |
Top clients or who we serve Global pharmaceutical companies, semiconductor manufacturers, battery industries, cosmetics and agrochemical firms; predominantly B2B. |
Key management Mr. Nareshkumar R. Patel (Chairman & Managing Director) leads, supported by an experienced senior management team. |
Our journey and innovations Evolved from partnership in 2004 to listed public company; launched new tech-enabled plants, secured 10 process patents, expanded electrolytes and solar projects, and implemented DCS automation. |
Where we operate Operations primarily in India with exports constituting 74% revenue, serving global markets including regulated pharma jurisdictions. |
Top products or what we offer Advanced pharmaceutical intermediates for APIs like Dolutegravir, specialty chemicals including parabens, battery chemicals, semiconductor chemicals, electrolytes, and key starting materials. |
Top brands Pharma intermediates like Dolutegravir intermediate, Trazodone intermediate; electrolytes additives; solar power initiatives; Baba Fine Chemicals portfolio. |
Raw materials needed Chemical raw materials including solvents, reagents, and specialty organic compounds sourced globally. |
Raw materials supplier Supplied by various chemical suppliers with emphasis on quality and regulatory compliance. |
Recurring vs cyclical contribution Revenue is largely recurring due to sustained pharma intermediates demand, with some cyclical exposure in specialty chemicals and battery sectors. |
Our industry position Strong R&D-driven specialty chemicals manufacturer with leadership in pharma intermediates and growing specialty chemicals verticals. |
Financial highlights FY25 consolidated revenue ₹10069 Mn, PAT ₹1604 Mn; revenue grew 40% YoY; EBITDA margin ~23%; exports contribute 74% of revenue. |
Geographical revenue split Domestic sales contribute 26%, exports 74%, reflecting strong global presence. |
Order book Healthy order book driven by ramp-up of CDMO and electrolytes projects, supporting strong future growth. |
Whats driving growth Growth driven by CDMO expansion, battery and semiconductor chemicals capex, cost efficiencies, and expanding global pharma demand. |
Our future plans Scaling electrolytes additives, new pilot plant for high-potent chemicals, further capacity expansions in specialty chemicals and advanced pharma intermediates. |
Our green promise Gold and Platinum EcoVadis accreditation, 15.8 MW solar power plants, energy conservation initiatives, and ESG focused manufacturing. |
Our people and values 879 employees fostering innovation, safety, diversity and inclusion with strong training and engagement programs. |
Key challenges ahead Managing raw material volatility, geopolitical risks, regulatory compliance, and accelerated global competition. |
Interesting facts Achieved GMP certification from Japan PMDA; reputed for cutting-edge patented processes; DCS automated plant deployment. |
Risks and strategy Mitigates supply chain risks, regulatory changes and market cyclicality via diversification, technological innovation, and robust risk governance. |
